209 related articles for article (PubMed ID: 26205409)
1. Topological sub-structural molecular design (TOPS-MODE): a useful tool to explore key fragments of human A3 adenosine receptor ligands.
Saíz-Urra L; Teijeira M; Rivero-Buceta V; Helguera AM; Celeiro M; Terán MC; Besada P; Borges F
Mol Divers; 2016 Feb; 20(1):55-76. PubMed ID: 26205409
[TBL] [Abstract][Full Text] [Related]
2. Affinity prediction on A3 adenosine receptor antagonists: the chemometric approach.
Luan F; Melo A; Borges F; Cordeiro MN
Bioorg Med Chem; 2011 Nov; 19(22):6853-9. PubMed ID: 21992803
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
Baraldi PG; Preti D; Borea PA; Varani K
J Med Chem; 2012 Jun; 55(12):5676-703. PubMed ID: 22468757
[No Abstract] [Full Text] [Related]
4. Recent advances on A₃ adenosine receptor antagonists by QSAR tools.
Luan F; Borges F; Cordeiro MN
Curr Top Med Chem; 2012; 12(8):878-94. PubMed ID: 22352915
[TBL] [Abstract][Full Text] [Related]
5. Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A
Lee Y; Hou X; Lee JH; Nayak A; Alexander V; Sharma PK; Chang H; Phan K; Gao ZG; Jacobson KA; Choi S; Jeong LS
J Med Chem; 2021 Sep; 64(17):12525-12536. PubMed ID: 34435786
[TBL] [Abstract][Full Text] [Related]
6. Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor.
Kim SK; Riley L; Abrol R; Jacobson KA; Goddard WA
Proteins; 2011 Jun; 79(6):1878-97. PubMed ID: 21488099
[TBL] [Abstract][Full Text] [Related]
7. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents.
Mailavaram RP; Al-Attraqchi OHA; Kar S; Ghosh S
Curr Pharm Des; 2019; 25(25):2772-2787. PubMed ID: 31333098
[TBL] [Abstract][Full Text] [Related]
8. QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.
Pran Kishore D; Balakumar C; Raghuram Rao A; Roy PP; Roy K
Bioorg Med Chem Lett; 2011 Jan; 21(2):818-23. PubMed ID: 21163647
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models.
Ranganathan A; Stoddart LA; Hill SJ; Carlsson J
J Med Chem; 2015 Dec; 58(24):9578-90. PubMed ID: 26592528
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
[TBL] [Abstract][Full Text] [Related]
11. Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation.
Varano F; Catarzi D; Squarcialupi L; Betti M; Vincenzi F; Ravani A; Varani K; Dal Ben D; Thomas A; Volpini R; Colotta V
Eur J Med Chem; 2015; 96():105-21. PubMed ID: 25874336
[TBL] [Abstract][Full Text] [Related]
12. A3 adenosine receptor: homology modeling and 3D-QSAR studies.
Almerico AM; Tutone M; Pantano L; Lauria A
J Mol Graph Model; 2013 May; 42():60-72. PubMed ID: 23567933
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacology of N
Yu J; Ahn S; Kim HJ; Lee M; Ahn S; Kim J; Jin SH; Lee E; Kim G; Cheong JH; Jacobson KA; Jeong LS; Noh M
J Med Chem; 2017 Sep; 60(17):7459-7475. PubMed ID: 28799755
[TBL] [Abstract][Full Text] [Related]
14. Structural Probing and Molecular Modeling of the A₃ Adenosine Receptor: A Focus on Agonist Binding.
Ciancetta A; Jacobson KA
Molecules; 2017 Mar; 22(3):. PubMed ID: 28287473
[TBL] [Abstract][Full Text] [Related]
15. Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents.
Paoletta S; Federico S; Spalluto G; Moro S
Methods Enzymol; 2010; 485():225-44. PubMed ID: 21050920
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
Federico S; Spalluto G
Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
[TBL] [Abstract][Full Text] [Related]
17. BCUT descriptors to predicting affinity toward A3 adenosine receptors.
González MP; Terán C; Teijeira M; Besada P; González-Moa MJ
Bioorg Med Chem Lett; 2005 Aug; 15(15):3491-5. PubMed ID: 15990306
[TBL] [Abstract][Full Text] [Related]
18. Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor.
Squarcialupi L; Catarzi D; Varano F; Betti M; Falsini M; Vincenzi F; Ravani A; Ciancetta A; Varani K; Moro S; Colotta V
Eur J Med Chem; 2016 Jan; 108():117-133. PubMed ID: 26638043
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and binding of homologated truncated 4'-thioadenosine derivatives at the human A3 adenosine receptors.
Lee HW; Kim HO; Choi WJ; Choi S; Lee JH; Park SG; Yoo L; Jacobson KA; Jeong LS
Bioorg Med Chem; 2010 Oct; 18(19):7015-21. PubMed ID: 20826090
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Optimization of Coumarin hA
Matos MJ; Vilar S; Vazquez-Rodriguez S; Kachler S; Klotz KN; Buccioni M; Delogu G; Santana L; Uriarte E; Borges F
J Med Chem; 2020 Mar; 63(5):2577-2587. PubMed ID: 31738058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
